RxDoctor Payments Data

Gabriel Sims

Family · Richland, WANPI 1659751279

Payments from drug & device makers

$2,910in general payments, 2019–2025

Across 146 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$344
  • Novo Nordisk$340
  • Pfizer$237
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$116
  • Corcept Therapeutics$112
  • plus $540 from 15 others

What the payments were for

  • Food & beverage$2,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,910 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$49,774
Medicare patients
132
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$54,042
MounjaroTirzepatide44$50,518
FarxigaDapagliflozin Propanediol11$17,657
JardianceEmpagliflozin14$14,383
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,833
Testosterone Cypionate43$2,441
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$1,612
Liothyronine Sodium45$1,559
Levothyroxine Sodium136$1,175
Oxycodone Hcl59$1,107
Duloxetine Hcl12$1,037
Fentanyl12$967
Gabapentin28$880
Methocarbamol39$836
Quetiapine Fumarate32$833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$340$54,04238 claims
Lilly USA, LLCMounjaro$19$50,51844 claims
AstraZenecaFarxiga$344$17,65711 claims
AbbVieArmour Thyroid$1,222$72913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.

Other family in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →